Patents by Inventor Payman Amiri

Payman Amiri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted benz-azoles and methods of their use as inhibitors of RAF kinase
    Patent number: 8614330
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: December 24, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Leonard Sung
  • Substituted benzimidazoles and methods of their use
    Patent number: 8592459
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: November 26, 2013
    Assignee: Novartis AG
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
    Publication number: 20120288501
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 15, 2012
    Applicant: Novartis Vaccines and Diagnostics, Inc. formerly known as Chiron Corporation
    Inventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung
  • Substituted benzazoles and methods of their use as inhibitors of raf kinase
    Patent number: 8299108
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: October 30, 2012
    Assignee: Novartis AG
    Inventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung
  • Quinazolines for PDK1 inhibition
    Patent number: 7932262
    Abstract: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: April 26, 2011
    Assignee: Novartis AG
    Inventors: Savithri Ramurthy, Xiaodong Lin, Sharadha Subramanian, Alice Rico, Xiaojong M. Wang, Rama Jain, Jeremy M. Murray, Stephen E. Basham, Robert L. Warne, Wei Shu, Yasheen Zhou, Jeffrey Dove, Mina Aikawa, Payman Amiri, Weibo Wang, Johanna M. Jansen, Allan S. Wagman, Keith B. Pfister, Simon Ng
  • SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE
    Publication number: 20100234394
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 16, 2010
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • QUINAZOLINES FOR PDK1 INHIBITION
    Publication number: 20100216767
    Abstract: The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
    Type: Application
    Filed: December 20, 2007
    Publication date: August 26, 2010
    Inventors: Mina Aikawa, Payman Amiri, Steven Bashman, Jeffrey Dove, Rama Jain, Xiaodong Lin, Jeremy Murray, Savithri Ramurthy, Alice Rico, Wei Shu, Sharadha Subramanian, Xiaojing Michael Wang, Robert L. Warne, Yasheen Zhou
  • SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
    Publication number: 20100196368
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: March 12, 2010
    Publication date: August 5, 2010
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Leonard Sung
  • Substituted benzimidazoles and methods of their use
    Patent number: 7732465
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: June 8, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    Patent number: 7728010
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: June 1, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J Poon, Savithri Ramurthy, Paul A Renhowe, Cynthia M Shafer, Sharadha Subramanian, Leonard Sung
  • QUINAZOLINES FOR PDK1 INHIBITION
    Publication number: 20100048561
    Abstract: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
    Type: Application
    Filed: April 5, 2007
    Publication date: February 25, 2010
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Savithri Ramurthy, Xiaodong Lin, Sharadha Subramanian, Alice C. Rico, Xiaojing M. Wang, Rama Jain, Jeremy M. Murray, Steven E. Basham, Robert L. Warne, Wei Shu, Yasheen Zhou, Jeffrey Dove, Mina Aikawa, Payman Amiri, Weibo Wang, Johanna M. Jansen, Allan S. Wagman, Keith B. Pfister, Simon Ng
  • Substituted benzimidazoles and methods of their use
    Publication number: 20090170904
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: December 5, 2008
    Publication date: July 2, 2009
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Substituted benzimidazoles and methods of their use
    Patent number: 7482367
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: January 27, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    Publication number: 20070299039
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: November 18, 2005
    Publication date: December 27, 2007
    Applicant: Chiron Corporation
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Levine, Christopher McBride, Daniel Poon, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Sharadha Subramanian, Leonard Sung
  • Substituted benzimidazoles and methods of their use
    Publication number: 20070161680
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: August 30, 2006
    Publication date: July 12, 2007
    Inventors: Mina Alkawa, Payman Amiri, Jeffrey Dove, Barry Levine, Christopher McBride, Teresa Pick, Daniel Poon, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    Patent number: 7071216
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: July 4, 2006
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Savithri Ramurthy, Payman Amiri, Barry Haskell Levine, Daniel J. Poon, Sharadha Subramanian, Leonard Sung, Wendy Fantl, Teresa Hansen, Christopher McBride, Cynthia M. Shafer
  • Substituted benzazoles and methods of their use as inhibitors of Raf kinase
    Publication number: 20040122237
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: September 29, 2003
    Publication date: June 24, 2004
    Inventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    Publication number: 20040087626
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: March 31, 2003
    Publication date: May 6, 2004
    Inventors: Paul A. Renhowe, Savithri Ramurthy, Payman Amiri, Barry Haskell Levine, Daniel J. Poon, Skaradha Subramanian, Leonard Sung, Wendy Fantl
  • Method of treatment of parasitic infection using IgE antagonists
    Patent number: 5656273
    Abstract: This invention concerns a method for the prevention and treatment of parasitic infection by administering an IgE antagonists. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: August 12, 1997
    Assignee: Genentech, Inc.
    Inventors: Payman Amiri, Mary Haak-Frendscho, Paula M. Jardieu